Today’s Stock On Watch: Celldex Therapeutics, Inc.’s Stock Is Sell After Today’s Huge Decline

Today's Stock On Watch: Celldex Therapeutics, Inc.'s Stock Is Sell After Today's Huge Decline

The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a huge mover today! The stock decreased 5.22% or $0.21 during the last trading session, hitting $3.81. About 2.08M shares traded hands. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 1.47% since April 27, 2016 and is downtrending. It has underperformed by 6.70% the S&P500.
The move comes after 7 months negative chart setup for the $396.61 million company. It was reported on Nov, 30 by Barchart.com. We have $3.70 PT which if reached, will make NASDAQ:CLDX worth $11.90M less.

Analysts await Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report earnings on February, 23. They expect $-0.31 earnings per share, up 6.06% or $0.02 from last year’s $-0.33 per share. After $-0.29 actual earnings per share reported by Celldex Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 6.90% negative EPS growth.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

Out of 12 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 7 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 58% are positive. Celldex Therapeutics has been the topic of 16 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm earned “Market Perform” rating on Monday, March 7 by Leerink Swann. On Tuesday, March 8 the stock rating was maintained by Cowen & Co with “Outperform”. H.C. Wainwright maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Tuesday, March 8 with “Buy” rating. Wedbush downgraded the shares of CLDX in a report on Monday, March 7 to “Neutral” rating. The firm has “Buy” rating given on Tuesday, August 11 by TH Capital. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Perform” rating given on Monday, March 7 by Oppenheimer. The company was maintained on Friday, February 26 by Cantor Fitzgerald. The stock has “Neutral” rating given by Guggenheim on Monday, March 7. The rating was maintained by Jefferies with “Hold” on Tuesday, August 9. The rating was maintained by Brean Capital with “Buy” on Tuesday, August 11.

According to Zacks Investment Research, “CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.”

More news for Celldex Therapeutics, Inc. (NASDAQ:CLDX) were recently published by: Fool.com, which released: “Why Celldex Therapeutics, Inc. Stock Tumbled 22% in October” on November 09, 2016. Fool.com‘s article titled: “Why Celldex Therapeutics, Inc. Stock Jumped Higher Again Today” and published on November 14, 2016 is yet another important article.

CLDX Company Profile

Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Firm drug candidates are derived from a set of complementary technologies, which have the ability to utilize the human immune system and enable the creation of therapeutic agents. The Firm is using the technologies to develop targeted immunotherapeutics consist of protein molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). The Company’s Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. The Company’s Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment